Columvi

Must be administered by a qualified healthcare professional. Have appropriate medical support available. Risk for CRS, neurologic toxicity (including ICANS). Initiate Columvi therapy with step-up dosing schedule and premedicate to reduce the risk for CRS. Ensure adequate hydration. Monitor and evaluate immediately if CRS (may need hospitalization) or neurologic toxicity (including ICANS) occurs; manage according to guidelines, and provide supportive care; withhold or discontinue based on severity (see full labeling). Active infections: do not initiate. Monitor for infections (may be serious) prior to and during treatment. Prior to initiation, give anti-hyperuricemics to those at risk for tumor lysis syndrome, and consider antiviral and PJP prophylaxis for infection risks. Bulky tumors or disease (in close proximity to airways or a vital organ): monitor closely during initial therapy. Monitor for signs/symptoms of compression or obstruction due to mass effect secondary to tumor flare. Embryo-fetal toxicity. Advise females of reproductive potential to use effective contraception during and for 1 month after the last dose. Pregnancy: exclude status prior to initiation. Nursing mothers: not recommended (during and for 1 month after the last dose).